Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

Inclusion criteria

For group 1 without trastuzumab :

• Patients must be ≥ 18 years old
• Patients with breast cancer stage I to III
• Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab
• Patients must have a social security coverage
• Patients able to speak, read and understand French

For group 2 with trastuzumab :

• Patients must be ≥ 18 years old
• Patients with breast cancer grade I to III
• Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab
• Patients must have a social security coverage
• Patients able to speak, read and understand French

Exclusion criteria

• History of cancer
• Previous chemotherapy
• Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular or neuromuscular disease)
• Pacemaker implantation
• Contraindication to physical condition evaluation
• Contraindication to local anesthesia required for microbiopsy
• Patients < 18 years old or patients ≥ 18 years old under guardianship, or supervision
• Psychiatric, musculoskeletal or neurologic disorders
• Women that are pregnant or breast-feeding